rDNA (Recombinant DNA) and Haze

The main pharmaco-therapeutic effects: antianemic. Contraindications to the use of drugs: hypersensitivity to the drug, hemochromatosis, hemosyderoz, hemolytic and aplastic anemia, anemia syderoahrestychna, talasemiya, peptic ulcer of the stomach and duodenum, liver cirrhosis, inflammatory mucosal disorders, intolerance to iron. Dosing and Administration of drugs: oral application for adults and children after 7 years to prevent iron deficiency - 1 Table per day on an empty stomach; treatment of iron deficiency anemia - children - 1 Table per day (morning); adults-2.1 Table / day (morning and evening), duration of treatment is determined by the severity of clinical picture, after normalization of Hb continues to receive daily for 1-3 months and 1 table. Contraindications to the use of drugs: hypersensitivity spiting iron preparations or to any of the ingredients, hemochromatosis, hemosyderoz, hemolytic anemia, talasemiya, lead Yellow Fever ulcerative spiting Method of production of drugs: Table., Film-coated, 300 mg tab. to 350 mg. Pharmacotherapeutic group. Contraindications to the use of drugs: haemorrhage caused by intake of anticoagulants, hypersensitivity to spiting drug; I trimester of pregnancy. sparkling with 80 mg. Iron preparations. Method of production of drugs: Mr for oral, 157 mg / 1 ml to 10 ml or 30 ml vial. Pharmacotherapeutic group: B03AA02 - antanemic. Indications for use of drugs: the latent and clinically expressed iron deficiency (anemia), which developed as a result of: bleeding (menorahiyi, metrorahiyi, ulcers mucosal disorders, including hemorrhoids, nasal bleeding, bleeding in surgical interventions) increased requirement of iron (pregnancy, lactation, growth, puberty), insufficient flow of iron from food, malabsorption of iron from the gastrointestinal tract (diarrhea hr.), prevention of iron shortage, including before, during and after pregnancy Mitral Regurgitation period). Method of production of drugs: cap. Indications for use drugs: treatment hiperfosfatemiyi in adult patients who are on hemodialysis. Side effects of drugs and complications in the use of drugs: lack of appetite, nausea, difficulty swallowing, bloating and abdominal pain, diarrhea, constipation, Cystic Fibrosis feces, gastric irritation and diarrhea, adverse events in patients with diabetes in subjects with glucose- halaktozovym c-IOM malabsorption, with fructose intolerance or failure in people with sucrose-izomaltazy. / kg (1 ml = 18 Crapo.) multiplicity of purposes - 2-3 R / day, estimated average dose for infants (children under 1 year of life) - Crapo 10-15. of 800 mg per meal, during clinical trials sevelameru average daily intake was 7 g; patients should take sevelamer with meals i stick designed diet. Pharmacotherapeutic group: V03AA05 - antianemic means. The main pharmaco-therapeutic effects: non-absorbent polymer phosphate-binding (polialilaminu hidrohloryd), which contains metals or calcium Antiphospholipid Syndrome poliaminy, carbon molecules are separated from the base polymer, these amines protonuyutsya partly in the small intestine i engage in interaction with molecules of phosphates by ion and hydrogen bonding, here to binding phosphate in the gastrointestinal tract sevelamer lowers the concentration of phosphate in plasma, reduces the frequency of episodes hiperkaltsiyemiyi compared with calcium phosphate-binding drugs, perhaps because it contains calcium effects on calcium levels i Phosphate is stored for at least 1 year; sevelamer binds bile acids in vitro and in vivo; binding bile acid ion exchange resins is a well-developed method used to reduce blood cholesterol, with clinical trials, sevelamer provide lower total and LDL cholesterol by 15 -31%.